GHSI — Guardion Health Sciences Share Price
0.000.00%
Last trade - 00:00- $12.75m
- $7.14m
- $12.25m
- 33
- 32
- 100
- 55
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.71 | ||
| Price to Tang. Book | 3.71 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.05 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -47.02% | ||
| Return on Equity | -86.11% | ||
| Operating Margin | -35.62% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.9 | 1.89 | 7.23 | 11.05 | 12.25 | 13.45 | 14.79 | 67.03% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Guardion Health Sciences, Inc. is a clinical nutrition company. The Company offers a portfolio of science-based, clinically supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients. The Company sells two ocular products: GlaucoCetin and Lumega-Z. GlaucoCetin is a dietary supplement in a capsule form designed specifically to provide nutrients to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health. Lumega-Z, its medical food product, has a formula designed to replenish and restore the macular protective pigment, simultaneously delivering critical and essential nutrients to the eye. As a medical food, Lumega-Z must be administered under the supervision of a physician or professional healthcare provider. It sells GlaucoCetin and Lumega-Z on its Website, guardionhealth.com.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- June 30th, 2015
- Public Since
- April 5th, 2019
- No. of Shareholders
- 80
- No. of Employees
- 9
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 1,284,156
- Address
- 2925 Richmond Avenue, Suite 1200, HOUSTON, 77098
- Web
- https://www.guardionhealth.com/
- Phone
- +null 18008735141
- Contact
- Scott Arnold
- Auditors
- WEINBERG & COMPANY PA
Upcoming Events for GHSI
Q3 2024 Guardion Health Sciences Inc Earnings Release
Guardion Health Sciences Inc Annual Shareholders Meeting
Similar to GHSI
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Aptorum
NASDAQ Capital Market
FAQ
What is the Guardion Health Sciences share price?
As of Today at 20:59 UTC, shares in Guardion Health Sciences are trading at $9.87. This share price information is delayed by 15 minutes.
How has the Guardion Health Sciences share price performed this year?
Shares in Guardion Health Sciences last closed at $9.87 and the price had moved by +43.25% over the past 365 days. In terms of relative price strength the Guardion Health Sciences share price has outperformed the S&P500 Index by +13.99% over the past year.
What are the analyst and broker recommendations for Guardion Health Sciences?
The overall consensus recommendation for Guardion Health Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Guardion Health Sciences dividend yield?
Guardion Health Sciences does not currently pay a dividend.
Does Guardion Health Sciences pay a dividend?
Guardion Health Sciences does not currently pay a dividend.
When does Guardion Health Sciences next pay dividends?
Guardion Health Sciences does not currently pay a dividend.
How do I buy Guardion Health Sciences shares?
To buy shares in Guardion Health Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Guardion Health Sciences?
As of the previous close price of $9.87, shares in Guardion Health Sciences had a market capitalisation of $12.67m.
Where are Guardion Health Sciences shares listed?
Here are the trading details for Guardion Health Sciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: GHSI
What kind of share is Guardion Health Sciences?
Based on an overall assessment of its quality, value and momentum Guardion Health Sciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Guardion Health Sciences share price forecast for 2024?
The analyst consensus target price for shares in Guardion Health Sciences is $40.00. That is 305.27% above the last closing price of $9.87.
Analysts covering Guardion Health Sciences currently have a consensus Earnings Per Share (EPS) forecast of -$2.40 for the next financial year.
What is the trend in the Guardion Health Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Guardion Health Sciences. Over the past six months, its share price has outperformed the S&P500 Index by +56.8%.
As of the last closing price of $9.87, shares in Guardion Health Sciences were trading +32.72% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Guardion Health Sciences PE Ratio?
The Guardion Health Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $9.87.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Guardion Health Sciences?
We do not have data on Guardion Health Sciences' directors